Compare EQ & QUMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQ | QUMS |
|---|---|---|
| Founded | 2017 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.0M | 115.8M |
| IPO Year | 2018 | N/A |
| Metric | EQ | QUMS |
|---|---|---|
| Price | $2.36 | $10.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 302.2K | 6.7K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,095,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $9.94 |
| 52 Week High | $2.70 | $10.23 |
| Indicator | EQ | QUMS |
|---|---|---|
| Relative Strength Index (RSI) | 62.86 | 70.14 |
| Support Level | $1.60 | $10.14 |
| Resistance Level | $2.49 | N/A |
| Average True Range (ATR) | 0.16 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 91.46 | 100.00 |
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
Quantumsphere Acquisition Corp is a newly organized blank check company.